-Shareholders Equity Deficiency has been Cured - Akari will Continue to be Listed and Traded on The Nasdaq Stock Market BOSTON and LONDON, November 19, 2024 …
[Read more...] about Akari Therapeutics Regains Full Nasdaq Compliance
Press Release
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio
- Secures $3.2m in PIPE Financing - $50m Term Sheet Obtained for Available Financing under Equity Line of Credit BOSTON and LONDON, November 14, 2024 (GLOBE …
Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio Inc. Merger
BOSTON and LONDON, November 8, 2024 (GLOBE NEWSWIRE) – Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies …
Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger
BOSTON and LONDON, October 14, 2024 (GLOBE NEWSWIRE) – Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company …
Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics
BOSTON and LONDON, September 17, 2024 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced …
[Read more...] about Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics
